Home » Stocks » Ocugen

Ocugen, Inc. (OCGN)

Stock Price: $0.320 USD 0.005 (1.59%)
Updated Oct 22, 2020 4:00 PM EDT - Market closed
After-hours: $0.317 -0.003 (-0.91%) Oct 22, 7:57 PM

Stock Price Chart

Key Info

Market Cap 51.85M
Revenue (ttm) 42,620
Net Income (ttm) -17.95M
Shares Out 135.01M
EPS (ttm) 0.32
PE Ratio 1.00
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Oct 22, 2020
Last Price $0.320
Previous Close $0.315
Change ($) 0.005
Change (%) 1.59%
Day's Open 0.320
Day's Range 0.312 - 0.327
Day's Volume 2,637,825
52-Week Range 0.170 - 2.050

More Stats

Market Cap 51.85M
Enterprise Value 43.07M
Earnings Date (est) Nov 6, 2020
Ex-Dividend Date n/a
Shares Outstanding 135.01M
Float 155.65M
EPS (basic) 0.32
EPS (diluted) 0.32
FCF / Share -0.16
Dividend n/a
Dividend Yield n/a
Earnings Yield 100.00%
FCF Yield n/a
Payout Ratio n/a
Shares Short 6.11M
Short Ratio 0.63
Short % of Float 3.92%
Beta n/a
PE Ratio 1.00
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 1,216.53
PB Ratio 3.00
Revenue 42,620
Operating Income -14.29M
Net Income -17.95M
Free Cash Flow -13.29M
Net Cash 8.78M
Net Cash / Share 0.05
Gross Margin 100.00%
Operating Margin -33,525.15%
Profit Margin -71,551.70%
FCF Margin -31,184.40%
ROA -60.93%
ROE -421.47%
ROIC 1,594.30%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (3)

Buy 2
Overweight 0
Hold 1
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

(165.63% upside)
Current: $0.320
Target: 0.85
*Average 12-month price target from 2 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Gross Profit-------0.03
Operating Income-14.16-16.14-24.95-30.31-31.82-32.66-16.85-14.97
Net Income-20.24-18.22-22.50-13.86-32.02-10.51-56.002.81
Shares Outstanding13.894.960.380.
Earnings Per Share-1.46-3.67-59.39-130.77-145.17-410.92-5,793.64170.97
Operating Cash Flow-16.89-11.63-23.02-25.74-30.03-17.94-15.28-12.23
Capital Expenditures-0.03-0.08-0.28-0.32-1.95-3.32-0.55-0.08
Free Cash Flow-16.92-11.71-23.30-26.06-31.98-21.26-15.84-12.31
Cash & Equivalents7.601.788.1232.0531.0558.669.2615.24
Total Debt1.418.500.180.761.341.75--
Net Cash / Debt6.19-6.727.9431.2829.7156.919.2615.24
Book Value11.02-12.71-11.2713.5728.2054.21-75.55-19.71
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Ocugen, Inc.
Country United States
Employees 16
CEO Shankar Musunuri

Stock Information

Ticker Symbol OCGN
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: OCGN


Ocugen, a clinical stage biopharmaceutical company, focuses on discovering, developing, and commercializing a pipeline of innovative therapies that address rare and underserved eye diseases. The company offers an ophthalmology portfolio that includes novel gene therapies, biologics, and small molecules, as well as targets a range of retinal and ocular surface diseases. Its pipeline includes OCU400 and OCU410 for the treatment of inherited retinal disorders; OCU200 for the treatment of wet-AMD, DME, and diabetic retinopathy; OCU100 for retinitis pigmentosa; and OCU300, which is in Phase III clinical trial for the treatment of ocular graft versus host diseases. The company has a strategic partnership with CanSino Biologics Inc. for gene therapy co-development and manufacturing. Ocugen, Inc. is based in Malvern, Pennsylvania.